The MBD technology used in our MethylCap kit is based on the very high affinity of the MethylCap protein for methylated DNA. This protein consists of the methyl-CpG-binding domain (MBD) of human MeCP2, as a C-terminal fusion with Glutathione-S-transferase (GST) containing an N-terminal His6-tag.
Diagenode’s MethylCap kit enables high enrichment of double-stranded DNA and a differential fractionation in function of the methylated CpG density. Fractionation reduces the complexity of samples and makes subsequent next generation sequencing easier. Prior to the MethylCap assay, DNA is first extracted and sheared using the Bioruptor® sonication device.
Cat. No. | Product | Format | Price | |
---|---|---|---|---|
C02020010 |
MethylCap kit The MethylCap kit allows to specifically capture DNA fragments containing methylated CpGs. The assay is based on the affinity purification of methylated DNA ... |
48 rxns | ||
C02020011 |
Auto MethylCap kit The Auto MethylCap kit allows to specifically capture DNA fragments containing methylated CpGs. The assay is based on the affinity purification of methylated... |
48 rxns | ||
C02020012 |
MethylCap protein The MethylCap protein has been extensively validated for specific isolation of DNA fragments containing methylated CpGs. It consists of the methyl-CpG-bindin... |
100 µg |